Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

Sponsor
Montreal Heart Institute
Study ID
NCT07524335
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Coronary Artery Disease
  • Subclinical Atherosclerotic Cardiovascular Disease

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Prescription of Aspirin — DRUG
    Aspirin 81 mg orally once daily
  • No prescription — DRUG
    No prescription of aspirin 81 mg orally once daily

Study Details

In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.

Key Dates

First listed
Apr 13, 2026
Start date
May 1, 2026
Status verified
May 2026
Primary completion
May 1, 2027
Completion
May 1, 2028

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Low-dose Aspirin Prescription
    Aspirin 81 mg orally once daily prescription
  • Other: No Prescription
    No prescription of aspirin 81 mg orally once daily

Primary Outcome Measure

Monthly Recruitment Rate [ Time Frame: 12 months following study enrollment initiation ]

Central Contacts

Related Studies